Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
22 Maio 2023 - 8:00AM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing targeted protein degradation
(TPD) to deliver novel small molecule protein degrader medicines,
today announced the appointment of Jeremy Chadwick, Ph.D., as Chief
Operating Officer. Dr. Chadwick joins Kymera with extensive
experience overseeing global development operations, regulatory and
program management at a range of biopharmaceutical companies. As a
member of the Company’s senior management team, Dr. Chadwick will
develop and execute near-term and long-range strategies to maximize
the impact of Kymera’s expanding pipeline.
“At Kymera, we have an unwavering commitment to our vision to be
a disease- and technology-agnostic, fully integrated global
biopharmaceutical company, using targeted protein degradation to
deliver medicines that will transform patients’ lives,” said Nello
Mainolfi, Ph.D., Founder, President and CEO, Kymera Therapeutics.
“Jeremy is a seasoned leader in the life sciences industry and will
help to guide the development of our first-in-class programs, scale
our capabilities and play a critical role in helping us accomplish
our ambitious goal of building a best-in-industry R&D
organization.”
“This is a transformational time for Kymera, with multiple
programs in the clinic across immunology and oncology and a
groundbreaking research engine rapidly creating and accelerating a
dynamic preclinical pipeline,” said Dr. Chadwick. “I am very
excited by the opportunity to help Kymera realize the potential of
this new generation of medicines by advancing these programs to
market and, ultimately, improving patients’ lives.”
Prior to Kymera, Dr. Chadwick served as Senior Vice President,
Head of Global Development Office at Takeda Pharmaceuticals. During
his time there, his responsibilities included Head of Global
Regulatory Affairs, as well as managing Global Drug Safety, Global
Clinical Supply Chain and several groups supporting Global
Development Operations. Before Takeda, Dr. Chadwick was Group Vice
President and Head of Clinical Development Operations at Shire
Pharmaceuticals. Earlier in his career, Dr. Chadwick held a number
of senior development roles with broad responsibilities including
program management, development operations, regulatory affairs,
biostatistics and data management at The Medicines Company, Synta
Pharmaceuticals, Vertex Pharmaceuticals and Glaxo Group Research.
Dr. Chadwick has been involved in several successful global
approvals spanning decades across multiple therapeutic areas.
Dr. Chadwick previously served as chairman of the Board of
Directors at Accumulus Synergy, a global organization developing a
transformative data exchange platform designed to enhance how
biopharmaceutical innovators and regulators bring safe and
effective medicines to patients faster. He earned his MS and PhD in
Statistics from the University of London and a BS in Mathematics
from Demontfort University in the United Kingdom.
About Kymera Therapeutics
Kymera is a biopharmaceutical company pioneering the field of
targeted protein degradation, a transformative approach to address
disease targets and pathways inaccessible with conventional
therapeutics. Kymera’s Pegasus platform is a powerful drug
discovery engine, advancing novel small molecule programs designed
to harness the body’s innate protein recycling machinery to degrade
dysregulated, disease-causing proteins. With a focus on undrugged
nodes in validated pathways, Kymera is advancing a pipeline of
novel therapeutic candidates designed to address the most promising
targets and provide patients with more effective treatments.
Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within
the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein,
providing the opportunity to treat patients with a broad range of
immune-inflammatory diseases, hematologic malignancies, and solid
tumors.
Founded in 2016, Kymera is headquartered in Watertown, Mass.
Kymera has been named a “Fierce 15” company by Fierce Biotech and
has been recognized by both the Boston Globe and the Boston
Business Journal as one of Boston’s top workplaces. For more
information about our people, science, and pipeline, please visit
www.kymeratx.com or follow us on Twitter or LinkedIn.
Cautionary Note Regarding Forward-Looking
Statements This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
implied and express statements regarding its: Pegasus™ platform;
Kymera Therapeutics' strategy, business plans and objectives for
the IRAK4, IRAKIMiD, STAT3 and MDM2 degrader programs; plans and
timelines for the preclinical and clinical development of its
product candidates, including the therapeutic potential, clinical
benefits and safety thereof; expectations regarding timing, success
and data announcements of current ongoing preclinical and clinical
trials; and the ability to initiate new clinical programs. The
words "may," “might,” "will," "could," "would," "should," "expect,"
"plan," "anticipate," "intend," "believe," “expect,” "estimate,"
“seek,” "predict," “future,” "project," "potential," "continue,"
"target" and similar words or expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Any forward-looking
statements in this press release are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, risks associated with: the impact of
COVID-19 on countries or regions in which we have operations or do
business, as well as on the timing and anticipated results of our
current and future preclinical studies and clinical trials, supply
chain, strategy and future operations; the delay of any current and
future preclinical studies or clinical trials or the development of
Kymera Therapeutics' drug candidates; the risk that the results of
current preclinical studies and clinical trials may not be
predictive of future results in connection with current or future
preclinical and clinical trials, including those for KT-474,
KT-333, KT-413 and KT-253; Kymera Therapeutics' ability to
successfully demonstrate the safety and efficacy of its drug
candidates; the timing and outcome of the Kymera Therapeutics'
planned interactions with regulatory authorities; obtaining,
maintaining and protecting its intellectual property; and Kymera
Therapeutics' relationships with its existing and future
collaboration partners. These and other risks and uncertainties are
described in greater detail in the section entitled "Risk Factors"
in the Quarterly Report on Form 10-Q for the quarter ended March
31, 2023 filed on May 4, 2023, as well as discussions of potential
risks, uncertainties, and other important factors in Kymera
Therapeutics' subsequent filings with the Securities and Exchange
Commission. In addition, any forward-looking statements represent
Kymera Therapeutics' views only as of today and should not be
relied upon as representing its views as of any subsequent date.
Kymera Therapeutics explicitly disclaims any obligation to update
any forward-looking statements. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Investor Contact: |
Media Contact: |
|
|
Bruce
Jacobs |
Todd
Cooper |
Chief
Financial Officer |
Senior Vice
President, Corporate Affairs |
investors@kymeratx.com |
media@kymeratx.com |
857-285-5300 |
857-285-5300 |
|
|
Chris
Brinzey |
|
Managing
Director, Westwicke |
|
chris.brinzey@westwicke.com |
|
339-970-2843 |
|
Kymera Therapeutics (NASDAQ:KYMR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Kymera Therapeutics (NASDAQ:KYMR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024